X

Trial Profile

An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 12 Months to 17 Years

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telavancin (Primary)
Indications Gram-positive infections
Focus Pharmacokinetics
Sponsors Cumberland Pharmaceuticals; Innoviva; Theravance Biopharma

Most Recent Events

10 Oct 2023 According to a Cumberland Pharmaceuticals media release, the results from this trial were published in the Antimicrobial Agents and Chemotherapy Journal.
10 Oct 2023 Results presented in the Cumberland Pharmaceuticals Media Release.
01 Feb 2022 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com